These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 9100989)
1. In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. Veal GJ; Barry MG; Khoo SH; Back DJ AIDS Res Hum Retroviruses; 1997 Apr; 13(6):481-4. PubMed ID: 9100989 [TBL] [Abstract][Full Text] [Related]
2. Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro. Hoggard PG; Manion V; Barry MG; Back DJ Br J Clin Pharmacol; 1998 Feb; 45(2):164-7. PubMed ID: 9491831 [TBL] [Abstract][Full Text] [Related]
3. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro. Hoggard PG; Sales SD; Kewn S; Sunderland D; Khoo SH; Hart CA; Back DJ Antivir Chem Chemother; 2000 Nov; 11(6):353-8. PubMed ID: 11227992 [TBL] [Abstract][Full Text] [Related]
4. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Kewn S; Veal GJ; Hoggard PG; Barry MG; Back DJ Biochem Pharmacol; 1997 Sep; 54(5):589-95. PubMed ID: 9337075 [TBL] [Abstract][Full Text] [Related]
5. The effect of hydroxyurea on the phosphorylation of zidovudine and lamivudine in human umbilical vein endothelial cells. McGuire TR; Hoie EB; Manouilov KK; Gwilt PG In Vitro Cell Dev Biol Anim; 2003; 39(7):280-2. PubMed ID: 14572303 [TBL] [Abstract][Full Text] [Related]
7. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. Feng JY; Johnson AA; Johnson KA; Anderson KS J Biol Chem; 2001 Jun; 276(26):23832-7. PubMed ID: 11328813 [TBL] [Abstract][Full Text] [Related]
8. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM; AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853 [TBL] [Abstract][Full Text] [Related]
9. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024 [TBL] [Abstract][Full Text] [Related]
10. Intracellular activation of 2',3'-dideoxyinosine and drug interactions in vitro. Kewn S; Hoggard PG; Henry-Mowatt JS; Veal GJ; Sales SD; Barry MG; Back DJ AIDS Res Hum Retroviruses; 1999 Jun; 15(9):793-802. PubMed ID: 10381167 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197 [TBL] [Abstract][Full Text] [Related]
12. Pyrimidine deoxynucleoside and nucleoside reverse transcriptase inhibitor metabolism in the perfused heart and isolated mitochondria. Morris GW; Laclair DD; McKee EE Antivir Ther; 2010; 15(4):587-97. PubMed ID: 20587852 [TBL] [Abstract][Full Text] [Related]
13. Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients. Robbins BL; Tran TT; Pinkerton FH; Akeb F; Guedj R; Grassi J; Lancaster D; Fridland A Antimicrob Agents Chemother; 1998 Oct; 42(10):2656-60. PubMed ID: 9756772 [TBL] [Abstract][Full Text] [Related]
14. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS. AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. Huang F; Allen L; Huang DB; Moy F; Vinisko R; Nguyen T; Rowland L; MacGregor TR; Castles MA; Robinson P J Clin Pharm Ther; 2012 Feb; 37(1):81-8. PubMed ID: 21128991 [TBL] [Abstract][Full Text] [Related]
17. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW; AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517 [TBL] [Abstract][Full Text] [Related]
18. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. Sommadossi JP AIDS; 1998; 12 Suppl 3():S1-8. PubMed ID: 15168717 [TBL] [Abstract][Full Text] [Related]
19. Finding a role for zalcitabine in the HAART era. Moyle GJ; Gazzard BG Antivir Ther; 1998; 3(3):125-37. PubMed ID: 10682130 [TBL] [Abstract][Full Text] [Related]
20. Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. Veal GJ; Wild MJ; Barry MG; Back DJ Br J Clin Pharmacol; 1994 Oct; 38(4):323-8. PubMed ID: 7833221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]